Report
(Sponsored) Oncodesign Precision Medicine - Targeted therapies for inflammation & oncology
We initiate coverage of Oncodesign Precision Medicine (OPM), a French clinical-stage biopharmaceutical company, with a target valuation range of EUR 1.9-2.7. We consider the company a compelling investment opportunity for numerous reasons:1/ OPM-101: RIPK2 inhibitor for immune checkpoint inhibitor-associated colitis (ICI-AC) and inflammatory bowel diseases (IBDs)Compelling scientific rationale and (pre)clinical data, indicating safety, preliminary efficacy, and selectivity, support RIPK2 inhibition as a mechanism of action to target both ICI-AC and IBD (ulcerative colitis & Crohn's disease).Immunomodulator (rather than immunosuppressor), acting via a distinct molecular pathway, allowing for convenient oral administration potentially in combo therapy while preserving the immune system's ability
Underlying
Oncodesign Precision Medicine
Provider
Degroof Petercam
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
David Seynnaeve, PhD
Other Reports on these Companies
Other Reports from Degroof Petercam
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.